Evidence map›Paper›PMID 35204596›Full record

ArticleDiagnostics (Basel, Switzerland)2022

2-[

Stefano Gay, Stefano Raffa, Anna De'Luca di Pietralata, Matteo Bauckneht, Lara Vera, Alberto Miceli, Manuela Albertelli, Silvia Morbelli, Massimo Giusti, Diego Ferone

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Role of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  4. FAPI PET/CT Imaging-An Updated Review.Diagnostics (Basel, Switzerland) · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stefano GayEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Stefano RaffaNuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Anna De'Luca di PietralataEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy.
Matteo BaucknehtNuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-1937-9116
Lara VeraEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Alberto MiceliNuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Manuela AlbertelliEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Silvia MorbelliNuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Massimo GiustiEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy.
Diego FeroneEndocrinology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To evaluate the role of 2-[

Indexed as

2-[18F]FDGPET/CTprognosisradioiodine refractory thyroid cancer

Identifiers

PMID35204596
PMCPMC8870858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.